Real-world application of the international myositis assessment and clinical studies group guidelines on cancer risk stratification
Main finding · Cancer within 3 years of IIM onsetResult — go to the resultOdds ratio 4.05Authors' conclusion
The IMACS stratification model effectively predicts cancer risk in IIM. However, real-world screening practices show inconsistencies, particularly in intermediate-risk patients.
Study context
- Population
- Idiopathic inflammatory myopathies (IIM) patients from five Italian rheumatology centres
- Participants
- 411 patients5 Italian centres
- Exposure
- IMACS-defined high vs intermediate vs standard cancer risk groups
- High-riskn = 180
- Intermediate-riskn = 156
- Standard-riskn = 75
- Outcome
- Cancer occurrence within three years of IIM diagnosis
- Follow-up
- 3 years
Methodological detailsmulticentre, logistic regression
- Multicentre
- Logistic regression
Main finding
Cancer within 3 years of IIM onset
Odds ratio
4.05
P = 0.026
As reported in the abstract
- Cancer diagnosed in all patients within 3 years of IIM onset
- 9.2%
Observational data: associations, not effects.
Further findings
| Outcome | OR | P value |
|---|---|---|
| Independent predictors of cancer: anti-TIF1γ | 12.3 | P < 0.001 |
| Independent predictors of cancer: anti-SAE1 | 11.9 | P = 0.012 |
Screening adherence
- Adherence varied: enhanced screening underused in intermediate-risk patients; screening declined over time
Original publication
Real-world application of the international myositis assessment and clinical studies group guidelines on cancer risk stratification. Rheumatology (Oxford). Published 4 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →